Natural antibodies to oxidation-specific epitopes: innate immune response and venous thromboembolic disease

被引:14
作者
Eichinger, S. [1 ,2 ]
Kyrle, P. A. [1 ,2 ]
Kammer, M. [3 ]
Eischer, L. [1 ]
Kozma, M. Ozsvar [4 ,5 ]
Binder, C. J. [4 ,5 ]
机构
[1] Med Univ Vienna, Dept Med 1, Waehringer Guertel 18-20, A-1090 Vienna, Austria
[2] Karl Landsteiner Inst Clin Thrombosis Res, Vienna, Austria
[3] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Sect Clin Biomet, Vienna, Austria
[4] Med Univ Vienna, Dept Lab Med, Vienna, Austria
[5] Austrian Acad Sci, Ctr Mol Med, Vienna, Austria
基金
奥地利科学基金会;
关键词
immunoglobulin M; innate immunity; OxLDL; phosphocholine; venous thrombosis; VON-WILLEBRAND-FACTOR; THROMBOTIC THROMBOCYTOPENIC PURPURA; FACTOR-CLEAVING PROTEASE; IIA-VONWILLEBRAND DISEASE; FACTOR A2 DOMAIN; ISCHEMIC-STROKE; BINDING-SITE; CONFORMATIONAL QUIESCENCE; MYOCARDIAL-INFARCTION; SCISSILE BOND;
D O I
10.1111/jth.13874
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and objectives: Natural antibodies to oxidation-specific epitopes protect from atherothrombotic events. Whether mechanisms of innate immunity are relevant in the pathogenesis of venous thromboembolism (VTE) is unknown. Patients/Methods: We measured plasma levels of immunoglobulin M (IgM) antibodies to oxidized low-density lipoproteins (OxLDL) and phosphocholine (PC) by enzyme linked immune assay in 663 patients with unprovoked VTE, who were prospectively followed after discontinuation of anticoagulation for a median of 8.8 years. The study endpoint was recurrent VTE. Results: IgM antibody levels to OxLDL and PC were higher in patients without compared to those with recurrent VTE (n = 174, 26.2%). For each doubling of OxLDL-IgM or PC-IgM the hazard ratio (HR) of recurrence was 0.88 (95% confidence interval [CI], 0.77-1.01) and 0.82 (95% CI, 0.71-0.94), respectively. After 5 years the probability of recurrence in patients with PC-IgM levels in the highest tertile (> 19.6 RLU/100 ms) was 13.0% (95% CI, 8.1-17.6%), compared with 21.1% (95% CI, 14.9-26.9%) in the middle tertile and 20.6% (95% CI, 14.7-26.0%) in the lowest tertile. The corresponding HR was 0.56 (0.39-0.82) for PC-IgM levels in the highest compared with the lowest tertile. Neither immunoglobulin G IgG antibody levels to OxLDL nor those to PC were associated with risk of VTE. Conclusion: Levels of natural IgM antibodies to oxidation-specific epitopes are inversely related to the risk of VTE.
引用
收藏
页码:31 / 35
页数:5
相关论文
共 112 条
[21]   Linker regions and flexibility around the metalloprotease domain account for conformational activation of ADAMTS-13 [J].
Deforche, L. ;
Roose, E. ;
Vandenbulcke, A. ;
Vandeputte, N. ;
Feys, H. B. ;
Springer, T. A. ;
Mi, L. Z. ;
Muia, J. ;
Sadler, J. E. ;
Soejima, K. ;
Rottensteiner, H. ;
Deckmyn, H. ;
De Meyer, S. F. ;
Vanhoorelbeke, K. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 (11) :2063-2075
[22]   Generation of Anti-Murine ADAMTS13 Antibodies and Their Application in a Mouse Model for Acquired Thrombotic Thrombocytopenic Purpura [J].
Deforche, Louis ;
Tersteeg, Claudia ;
Roose, Elien ;
Vandenbulcke, Aline ;
Vandeputte, Nele ;
Pareyn, Inge ;
De Cock, Elien ;
Rottensteiner, Hanspeter ;
Deckmyn, Hans ;
De Meyer, Simon F. ;
Vanhoorelbeke, Karen .
PLOS ONE, 2016, 11 (08)
[23]   Reduced ADAMTS13 levels in patients with acute and chronic cerebrovascular disease [J].
Denorme, Frederik ;
Kraft, Peter ;
Pareyn, Inge ;
Drechsler, Christiane ;
Deckmyn, Hans ;
Vanhoorelbeke, Karen ;
Kleinschnitz, Christoph ;
De Meyer, Simon F. .
PLOS ONE, 2017, 12 (06)
[24]   ADAMTS13-mediated thrombolysis of t-PA-resistant occlusions in ischemic stroke in mice [J].
Denorme, Frederik ;
Langhauser, Friederike ;
Desender, Linda ;
Vandenbulcke, Aline ;
Rottensteiner, Hanspeter ;
Plaimauer, Barbara ;
Francois, Olivier ;
Andersson, Tommy ;
Deckmyn, Hans ;
Scheiflinger, Friedrich ;
Kleinschnitz, Christoph ;
Vanhoorelbeke, Karen ;
De Meyer, Simon F. .
BLOOD, 2016, 127 (19) :2337-2345
[25]   Probing ADAMTS13 Substrate Specificity using Phage Display [J].
Desch, Karl C. ;
Kretz, Colin ;
Yee, Andrew ;
Gildersleeve, Robert ;
Metzger, Kristin ;
Agrawal, Nidhi ;
Cheng, Jane ;
Ginsburg, David .
PLOS ONE, 2015, 10 (04)
[26]   The role of ADAMTS13 in acute myocardial infarction: cause or consequence? [J].
Eerenberg, Elise S. ;
Teunissen, Paul F. A. ;
van den Born, Bert-Jan ;
Meijers, Joost C. M. ;
Hollander, Maurits R. ;
Jansen, Matthijs ;
Tijssen, Ruben ;
Belien, Jeroen A. M. ;
van de Ven, Peter M. ;
Aly, Mohamed F. ;
Kamp, Otto ;
Niessen, Hans W. ;
Kamphuisen, Pieter Willem ;
Levi, Marcel ;
van Royen, Niels .
CARDIOVASCULAR RESEARCH, 2016, 111 (03) :194-203
[27]   Multi-step binding of ADAMTS-13 to von Willebrand factor [J].
Feys, H. B. ;
Anderson, P. J. ;
Vanhoorelbeke, K. ;
Majerus, E. M. ;
Sadler, J. E. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (12) :2088-2095
[28]   Thrombotic thrombocytopenic purpura directly linked with ADAMTS13 inhibition in the baboon (Papio ursinus) [J].
Feys, Hendrik B. ;
Roodt, Jan ;
Vandeputte, Nele ;
Pareyn, Inge ;
Lamprecht, Seb ;
van Rensburg, Walter J. ;
Anderson, Patricia J. ;
Budde, Ulrich ;
Louw, Vernon J. ;
Badenhorst, Philip N. ;
Deckmyn, Hans ;
Vanhoorelbeke, Karen .
BLOOD, 2010, 116 (12) :2005-2010
[29]   Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family [J].
Fujikawa, K ;
Suzuki, H ;
McMullen, B ;
Chung, D .
BLOOD, 2001, 98 (06) :1662-1666
[30]   Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura [J].
Furlan, M ;
Robles, R ;
Solenthaler, M ;
Wassmer, M ;
Sandoz, P ;
Lammle, B .
BLOOD, 1997, 89 (09) :3097-3103